New Delhi: India’s largest drug firm Ranbaxy Laboratories said on 22 February that its Romanian subsidiary Terapia has received manufacturing and import authorisation from the country’s regulatory agencies as per European Union (EU) norms.
Terapia-Ranbaxy has been given a go ahead for batch testing and release for its products manufactured outside EU,following the inspection carried out by Romanian Regulatory Agency in early February.
The company intends to transfom Terapia-Ranbaxy into a strategic regional hub for its operations in Europe. Ranbaxy had acquired Terapia for about $330 million (Rs 14570 million)last year.
“The regulatory agency acknowledged the good systems and process put in place at our Cluj-Napoca (Romania) and also the quality of the laboratory and technology transfer”, said Terapia-Ranbaxy Chief Executive Officer Dragos Damian.
The authorisation aligns quality systems in Terapia-Ranbaxy with EU norms, paving way for the company to strengthen its position in European market, he added.